Hostname: page-component-7c8c6479df-fqc5m Total loading time: 0 Render date: 2024-03-28T03:43:30.784Z Has data issue: false hasContentIssue false

Disruptive mood dysregulation disorder: does variance in treatment responses also add to the conundrum? The widening gap in the evidence is a signal needing attention

Published online by Cambridge University Press:  18 November 2021

Mayank Gupta*
Affiliation:
Clarion Psychiatric Centre, Clarion, Pennsylvania, USA
Nihit Gupta
Affiliation:
Reynolds Memorial Hospital, Glendale, West Virginia, USA
*
*Author for correspondence: Mayank Gupta, MD, Email: mayank6nov@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

The new diagnosis of disruptive mood dysregulation disorder (DMDD) was introduced in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, to address the overdiagnosis of bipolar disorder in children and adolescents. However, there are ongoing debates about its nosology given chronic persistent irritability in children and adolescents has contextual valence. Those meeting the criteria for DMDD may, in fact, have an oppositional defiant disorder, attention deficit hyperactivity disorder, or other behavioral disorders. Similarly, in the last few years, there are many different types of treatment studies that have also yielded mixed results. These counterintuitive findings need a meticulous review for a wider debate given its clinical utility for patients, families, and practicing clinicians.

Type
Editorial
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Since the introduction of disruptive mood dysregulation disorder (DMDD) in 2014 as a clinical entity, there have been many unanswered questions. There is an ongoing debate about its nosology, since the chronic persistent irritability in children and adolescents has contextual valence. In the last few years, different types of treatment studies have also yielded mixed results (Table 1). These findings further widen the debate given its clinical utility for patients, families, and practicing clinicians. The widespread criticism about the validity of DMDD predates 2014. There is no consensus on evidence-based treatment strategies for DMDD, and the aim is to examine the hypothesis if there is a high variance in treatment responses in the recent empirical research. We performed a literature search from Psych INFO, PubMed, Medline, and Google Scholar until 2021. The search strategy included the following key terms: “adolescents,” “ADHD,” “aggression,” “bipolar disorder,” “children,” “disruptive behaviors,” “irritability,” “oppositional defiant disorder,” “ODD,” “rage,” “temper outbursts,” and “treatment” as main subject headings or text words in titles and abstracts. We identified n = 20 relevant articles among which 11 were specific about treatment, and others highlighted issues with the validity of the diagnosis.

Table 1. Summary of Studies.

Abbreviations: CTP, citalopram; DMDD, disruptive mood dysregulation disorder; IPT, interpersonal therapy; IPT-MBD, interpersonal psychotherapy for mood and behavior dysregulation; MPH, methylphenidate.

The emerging evidence is weak. But it strengthens the chorus challenging the validity of DMDD due to its overlapping symptoms with oppositional defiant disorder, attention deficit hyperactivity disorder, and major depressive disorder. A promising diffusion tensor imaging study reported discrete alternations in white matter microstructure in DMDD as compared to altered myelination in bipolar disorder. The epigenetic mechanisms of hypermethylated DNA were also studied to link it with its possible etiology without success. The psychopharmacological treatment studies used stimulant medication, antidepressants, antipsychotics, amantadine, and naltrexone with limited generalizability. Interpersonal therapy, cognitive behavioral therapy, and parent management training have some efficacy in symptom reduction. It is also suggested to revise the age of onset in the diagnostic criterion, because it excludes children of age <6 years, and the core symptoms are present in early childhood, and subsequently, its impairments when left untreated have poor overall outcomes.

The rationale for creating DMDD as a separate category has been counterintuitive and led to diagnostic uncertainly and hesitancy among clinicians. The limited evidence suggests a more heterogeneous condition with symptoms overlapping of other disorders and responds to diverse strategies. Although chronic persistent irritability is the area of focus for new research, more clarity is needed.

Acknowledgment

None.

Funding Statement

The work received no specific grant from any funding agency, commercial, or not-for-profit sectors.

Disclosure

The authors do not have anything to disclose.

References

Benarous, X, Renaud, J, Breton, JJ, Cohen, D, Labelle, R, Guilé, JM. Are youths with disruptive mood dysregulation disorder different from youths with major depressive disorder or persistent depressive disorder? J Affect Disord. 2020;265:207215.CrossRefGoogle ScholarPubMed
Blok, E, White, T. Editorial: white matter matters: neurobiological differences between pediatric bipolar disorder and disruptive mood dysregulation disorder. J Am Acad Child Adolesc Psychiatry. 2020;59(10):11281129.CrossRefGoogle ScholarPubMed
Wiggins, JL, Briggs-Gowan, MJ, Estabrook, R, et al. Identifying clinically significant irritability in early childhood. J Am Acad Child Adolesc Psychiatry. 2018;57(3):191199.e2.CrossRefGoogle ScholarPubMed
Carola, V, Cimino, S, Bussone, S, Cerniglia, L, Tambelli, R. Children with disruptive mood dysregulation disorder and psychopathological risk in their mothers: the function of global DNA methylation. Front Psychiatry. 2021;12:593500.CrossRefGoogle ScholarPubMed
Lochman, JE, Evans, SC, Burke, JD, et al. An empirically based alternative to DSM-5’s disruptive mood dysregulation disorder for ICD-11. World Psychiatry. 2015;14(1):3033.CrossRefGoogle ScholarPubMed
Salum, GA. Editorial: the role of computational models to uncover the cognitive mechanisms underpinning disruptive mood dysregulation disorder. J Am Acad Child Adolesc Psychiatry. 2021;60(5):577578.CrossRefGoogle ScholarPubMed
Laporte, PP, Matijasevich, A, Munhoz, TN, et al. Disruptive mood dysregulation disorder: symptomatic and syndromic thresholds and diagnostic operationalization. J Am Acad Child Adolesc Psychiatry. 2021;60(2):286295.CrossRefGoogle ScholarPubMed
Tseng, WL. Editorial: a transdiagnostic symptom requires a transdiagnostic approach: neural mechanisms of pediatric irritability. J Am Acad Child Adolesc Psychiatry. 2020;59(12):13271329.CrossRefGoogle Scholar
Linke, JO, Adleman, NE, Sarlls, J, et al. White matter microstructure in pediatric bipolar disorder and disruptive mood dysregulation disorder. J Am Acad Child Adolesc Psychiatry. 2020;59(10):11351145.CrossRefGoogle ScholarPubMed
Carlson, GA, Klein, DN. Editorial: antidepressants to the rescue in severe mood dysregulation and disruptive mood dysregulation disorder? J Am Acad Child Adolesc Psychiatry. 2020;59(3):339341.CrossRefGoogle Scholar
Towbin, K, Vidal-Ribas, P, Brotman, MA, et al. A double-blind randomized placebo-controlled trial of citalopram adjunctive to stimulant medication in youth with chronic severe irritability. J Am Acad Child Adolesc Psychiatry. 2020;59(3):350361.CrossRefGoogle ScholarPubMed
Winters, DE, Fukui, S, Leibenluft, , Hulvershorn, LA. Improvements in irritability with open-label methylphenidate treatment in youth with comorbid attention deficit/hyperactivity disorder and disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol. 2018;28(5):298305.CrossRefGoogle ScholarPubMed
Tourian, L, LeBoeuf, A, Breton, JJ, et al. Treatment options for the cardinal symptoms of disruptive mood dysregulation disorder. J Can Acad Child Adolesc Psychiatry. 2015;24(1):4154.Google ScholarPubMed
Rice, T, Simon, H, Barckak, D, et al. Amantadine for treatment of disruptive mood dysregulation disorder symptoms. J Child Adolesc Psychopharmacol. 2019;29(8):642646.CrossRefGoogle ScholarPubMed
Loy, JH, Merry, SN, Hetrick, SE, Stasiak, K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev.. 2017;8(8):CD008559. Published 2017 Aug 9. doi:10.1002/14651858.CD008559.pub3.Google ScholarPubMed
Pan, PY, Fu, AT, Yeh, CB. Aripiprazole/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: an open-label study. J Child Adolesc Psychopharmacol. 2018;28(10):682689.CrossRefGoogle ScholarPubMed
Miller, L, Hlastala, SA, Mufson, L, Leibenluft, E, Yenokyan, G, Riddle, M. Interpersonal psychotherapy for mood and behavior dysregulation: pilot randomized trial. Depress Anxiety. 2018;35(6):574582.CrossRefGoogle ScholarPubMed
Parmar, A, Vats, D, Parmar, R, Aligeti, M. Role of naltrexone in management of behavioral outbursts in an adolescent male diagnosed with disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol. 2014;24(10):594595.CrossRefGoogle Scholar
Figure 0

Table 1. Summary of Studies.